Dual Promoter-Controlled Oncolytic Adenovirus CG5757 Has Strong Tumor Selectivity and Significant Antitumor Efficacy in Preclinical Models

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-1757
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Potent Antitumor Effect of Tumor Microenvironment-Targeted Oncolytic Adenovirus Against Desmoplastic Pancreatic Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

The hTERT Promoter Enhances the Antitumor Activity of an Oncolytic Adenovirus Under a Hypoxic Microenvironment

PLoS ONE
Multidisciplinary
2012English

61PArming Oncolytic Adenovirus With FAP-targeting Bispecific T-Cell Engager to Improve Antitumor Efficacy

Annals of Oncology
MedicineOncologyHematology
2017English

LY3009120, a panRAF Inhibitor, Has Significant Anti-Tumor Activity in BRAF and KRAS Mutant Preclinical Models of Colorectal Cancer

Oncotarget
Oncology
2016English

Therapeutic Efficacy of an hTERT Promoter-Driven Oncolytic Adenovirus That Expresses Apoptin in Gastric Carcinoma

International Journal of Molecular Medicine
MedicineGenetics
2012English

Significant Therapeutic Efficacy With Combined Radioimmunotherapy and Cetuximab in Preclinical Models of Colorectal Cancer

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2015English

Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy Against Advanced Models of Human Colon Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Efficacy of a New Oncolytic Adenovirus Armed With IL-13 Against Oral Carcinoma Models

OncoTargets and Therapy
OncologyPharmacology
2019English

Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy